Ocrevus (Ocrelizumab) for Multiple Sclerosis

Overview
Ocrevus is a prescription drug approved by the Food and Drug Administration (FDA) to treat both relapsing and primary progressive forms of multiple sclerosis. Ocrevus is also referred to by its drug name, Ocrelizumab.

Ocrevus is a biologic immunomodulator, or in other words, a drug that modulates the immune system. Ocrevus is a genetically engineered antibody, or protein used by the immune system to identify and neutralize substances. Ocrevus is believed to work by reducing the number of CD20-positive B cells, a type of immune system cell involved in nerve cell attacks.

How do I take it?
Ocrevus is administered by intravenous infusion in a medical setting once every six months after initial loading doses.

Ocrevus comes as a single-use vial.

Side effects
The FDA-approved label for Ocrevus lists common side effects including infusion reactions such headache, dizziness, fever, nausea, itching, rash, flushed skin, low blood pressure, and fast heartbeat, and infections of the skin and respiratory tract.

Rare but serious side effects listed for Ocrevus include severe infusion reactions and increased risk for some types of cancer.

For more details about this treatment, visit:

Ocrevus - Roche
https://www.ocrevus.com/